I agree with you and Nader. MTNBC alone is a 96 Bi
Post# of 148188
Then add in after a cancer basket BLA and add many Immunodeficiency diseases indications for BLA or label extensions and it even seems like quadruple stock price is low balling the future of the stock price. It would appear that there is no ceiling to the potential of our little molecule.
I am hopeful for Covid to set up this little company on its way to proving many more indications with the revenue world wide from Covid. Just think... we all are or could be a big part of history going forward with Leronlimab as the next big block buster for some of the most debilitating diseases known to mankind. It would be truly a miracle and I hope for the best.